CanSino Biologics

CanSino Biologics Inc. is a Chinese biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of vaccine products for human use. The company is known for its innovative approach to vaccine development and has gained international recognition for its work on the COVID-19 pandemic.
History[edit]
CanSino Biologics was founded in 2009 in Tianjin, China. The company was established by a group of scientists with extensive experience in the vaccine industry, aiming to develop high-quality vaccines for the global market. Since its inception, CanSino has focused on developing vaccines for infectious diseases, including tuberculosis, meningitis, and Ebola virus disease.
COVID-19 Vaccine Development[edit]
During the COVID-19 pandemic, CanSino Biologics developed a COVID-19 vaccine known as Convidecia. This vaccine is based on a recombinant adenovirus type-5 vector (Ad5) and was one of the first COVID-19 vaccines to be approved for emergency use in China. Convidecia is administered as a single-dose vaccine, which differentiates it from many other COVID-19 vaccines that require two doses.
Technology and Innovation[edit]
CanSino Biologics utilizes advanced technologies in its vaccine development processes. The company employs recombinant DNA technology and viral vector platforms to create effective and safe vaccines. The use of adenovirus vectors, such as in the Convidecia vaccine, allows for the delivery of genetic material into host cells, prompting an immune response without causing disease.
Global Impact[edit]
CanSino's Convidecia vaccine has been distributed to several countries around the world, contributing to the global effort to combat the COVID-19 pandemic. The vaccine's single-dose regimen and ease of storage and transportation have made it an attractive option for many countries, particularly those with limited healthcare infrastructure.
Related Pages[edit]
-
Logo of CanSino Biologics
-
Lox and smoked whitefish
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian